Literature DB >> 20149036

Clinical features of fetal growth restriction complicated later by preeclampsia.

Minoru Mitani1, Yoshio Matsuda, Yasuo Makino, Yoshika Akizawa, Hiroaki Ohta.   

Abstract

OBJECTIVE: To assess the maternal and perinatal outcome of preeclampsia with fetal growth restriction (FGR) and to assess the risk factors of FGR complicated later by preeclampsia. SUBJECTS AND METHODS: A cohort of women with preeclampsia and/or FGR (n = 306) were retrospectively reviewed. First, the maternal and perinatal outcome were compared between preeclampsia with FGR (n = 37) and preeclampsia without FGR (n = 96). Second, the clinical findings of FGR followed later by preeclampsia (n = 24) were compared to FGR without preeclampsia (n = 149).
RESULTS: The incidence of severe hypertension and critical maternal complications in women with preeclampsia with FGR was significantly higher than in those with preeclampsia without FGR. In women diagnosed with FGR, 13.8% (24/173) developed preeclampsia later. In this group, FGR was diagnosed at 28.8 gestational weeks, which was then complicated by preeclampsia at a mean of 32.6 gestational weeks, and delivered at 33.3 gestational weeks. The diagnosis of FGR was earlier and the incidence of proteinuria at entry was more common in women with FGR complicated later by preeclampsia than in those with FGR without preeclampsia (45.8% vs 4.7%; P < 0.001).
CONCLUSIONS: Preeclampsia with FGR is severe condition which can possibly adversely affect the maternal condition. About 15% of all mothers diagnosed with FGR developed preeclampsia afterwards; therefore, those with FGR are considered to be candidates for close monitoring for the clinical manifestation of preeclampsia, and those with early-onset FGR with proteinuria may represent a high-risk group for preeclampsia.

Entities:  

Mesh:

Year:  2009        PMID: 20149036     DOI: 10.1111/j.1447-0756.2009.01120.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  9 in total

1.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016

2.  Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study.

Authors:  Jane Weiler; Stephen Tong; Kirsten R Palmer
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

3.  FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia.

Authors:  Paula Quintero-Ronderos; Karen Marcela Jiménez; Clara Esteban-Pérez; Diego A Ojeda; Sandra Bello; Dora Janeth Fonseca; María Alejandra Coronel; Harold Moreno-Ortiz; Diana Carolina Sierra-Díaz; Elkin Lucena; Sandrine Barbaux; Daniel Vaiman; Paul Laissue
Journal:  Mol Med       Date:  2019-08-08       Impact factor: 6.354

4.  Distinct placental molecular processes associated with early-onset and late-onset preeclampsia.

Authors:  Zhonglu Ren; Yunfei Gao; Yue Gao; Guanmei Liang; Qian Chen; Sijia Jiang; Xiaoxue Yang; Cuixia Fan; Haizhen Wang; Jing Wang; Yi-Wu Shi; Chaoqun Xiao; Mei Zhong; Xinping Yang
Journal:  Theranostics       Date:  2021-03-05       Impact factor: 11.556

5.  Fetal growth restriction as the initial finding of preeclampsia is a clinical predictor of maternal and neonatal prognoses: a single-center retrospective study.

Authors:  Masaya Takahashi; Shintaro Makino; Kyoko Oguma; Haruka Imai; Ai Takamizu; Akari Koizumi; Koyo Yoshida
Journal:  BMC Pregnancy Childbirth       Date:  2021-10-06       Impact factor: 3.007

6.  Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction.

Authors:  Ryo Kiyokoba; Takeshi Uchiumi; Mikako Yagi; Takahiro Toshima; Shigehiro Tsukahara; Yasuyuki Fujita; Kiyoko Kato; Dongchon Kang
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

7.  Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia.

Authors:  Jovian M Wat; Krista Hawrylyshyn; Dora Baczyk; Iain R Greig; John C Kingdom
Journal:  Biol Reprod       Date:  2018-11-01       Impact factor: 4.285

8.  Glycemic control and fetal growth of women with diabetes mellitus and subsequent hypertensive disorders of pregnancy.

Authors:  Mamoru Morikawa; Emi Kato-Hirayama; Michinori Mayama; Yoshihiro Saito; Kinuko Nakagawa; Takeshi Umazume; Kentaro Chiba; Satoshi Kawaguchi; Kazuhiko Okuyama; Hidemichi Watari
Journal:  PLoS One       Date:  2020-03-16       Impact factor: 3.240

9.  The association of hypertensive disorders of pregnancy with small for gestational age and intertwin birthweight discordance.

Authors:  Dongxin Lin; Caihong Luo Bd; Gengdong Chen; Dazhi Fan; Zheng Huang; Pengsheng Li; Shuzhen Wu; Shaoxin Ye Bd; Huiting Ma; Jiaming Rao; Huishan Zhang; Ting Chen; Meng Zeng; Xiaoling Guo; Zhengping Liu
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-05-20       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.